Cytomegalovirus Disease in Renal Transplanted Patients: Prevalence, Determining Factors, and Influence on Graft and Patients Outcomes
Authors:
- Carlo Maria AlfieriCACarlo Maria Alfieri
- Paolo MolinariPMPaolo Molinari
- Mariateresa GandolfoMGMariateresa Gandolfo
- Mariarosaria CampiseMCMariarosaria Campise
- Donata CresseriDCDonata Cresseri
- Anna RegaliaARAnna Regalia
- Evaldo FaviEvaldo Favi
- Min LiMLMin Li
- Masami IkehataMIMasami Ikehata
- Serena DelbueSDSerena Delbue
- Piergiorgio MessaPiergiorgio Messa
Open Access
Abstract
The prevalence and the factors related to cytomegalovirus (CMV) disease (CMVd) during the 1st year of renal transplantation (RTx) and the relationship between CMVd and early and long-term graft and RTx-patient (RTx-p) survival were evaluated. In 505 RTx-p, followed up for 8(5–11) years, data were recorded after 1-(T1) and 12-(T12) months of RTx. CMVd was defined either by CMV replication without clinical signs of disease (CMVr, 43%), or CMV replication with signs of disease (CMVs, 57%). During the 1st year of RTx, 45% of RTx-p had CMVd (CMVd+). CMVd+ patients were older than CMVd− patients. Female gender and Donor CMV-IgG+ (CMV IgG−D+)/recipient IgG- (CMV IgG−R-) status were more prevalent in CMVd+. At T1, CMVd+ had lower albumin, haemoglobin, and higher uric-acid and reactive C-protein than CMVd− and, at T1 and T12, received more steroids. Albumin-T1 was the unique factor in determining CMVd+, maintaining its significance also after the inclusion of IgG−D+/IgG−R− status to the model. CMVs had higher prevalence of CMV IgG-D+/IgG-R- than CMVr. CMVd, CMVr, and CMVs had no impact on graft loss (11% of RTx-p) and RTx-p death (8% of RTx-p). CMVd is highly prevalent during the 1st year of RTx. Albumin-T1 influences CMVd insurgence. CMVd did not impact on RTx and RTx-p loss.Keywords
This publication has 47 references indexed in Scilit:
- Immune Dysfunction in Uremia—An UpdateToxins, 2012
- Post–Renal Transplant Cytomegalovirus Infection: Study of Risk FactorsTransplantation Proceedings, 2012
- Human Cytomegalovirus and Kidney Transplantation: A Clinician's UpdateAmerican Journal of Kidney Diseases, 2011
- New Developments in the Management of Cytomegalovirus Infection after Solid Organ TransplantationDrugs, 2010
- The Risk Factors for Cytomegalovirus Syndrome and Tissue-invasive Cytomegalovirus Disease in Liver Transplant Recipients Who Have Cytomegalovirus AntigenemiaTransplantation Proceedings, 2010
- Delayed-Onset Primary Cytomegalovirus Disease and the Risk of Allograft Failure and Mortality after Kidney TransplantationClinical Infectious Diseases, 2008
- Prevalence of Chronic Kidney Disease in the United StatesJAMA, 2007
- How corticosteroids control inflammation: Quintiles Prize Lecture 2005British Journal of Pharmacology, 2006
- Immune escape and exploitation strategies of cytomegaloviruses: impact on and imitation of the major histocompatibility systemCellular Microbiology, 2004
- Cytomegalovirus infection in day care centers in Rome, Italy: Viral excretion in children and occupational risk among workersJournal of Medical Virology, 1988